2011年1月20〜22日に米国サンフランシスコにて開催された2011年 消化器癌シンポジウム(2011 Gastrointestinal Cancers
Symposium)より、大腸癌や胃癌などの注目演題のレポートをお届けします。
演題レポートの冒頭には “Expert's view”として、臨床研究の第一線で活躍する監修ドクターのコメントを掲載しています。
演題レポートの冒頭には “Expert's view”として、臨床研究の第一線で活躍する監修ドクターのコメントを掲載しています。
2011年2月10日 サイトをアップしました。

A Randomized Phase II Study of PEP02, Irinotecan, or Docetaxel as a Second Line Therapy in Patients with Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (PEP0206).
David Cunningham, et al. |
Randomized phase III study of S-1 alone versus S-1 + docetaxel in the treatment for advanced gastric cancer (The START trial)
Yeul Hong Kim, et al. |
EXPERT-C: A randomized phase II European multicenter trial of neoadjuvant chemotherapy (capecitabine/oxaliplatin) and chemoradiation (CRT) with or without cetuximab followed by total mesorectal excision (TME) in patients with MRI-defined high-risk rectal cancer.
Alice Dewdney, et al. |
A Randomized, Phase 1/2 Trial of AMG 102 or AMG 479 in Combination With Panitumumab vs Panitumumab Alone in Patients With Wild-Type KRAS Metastatic Colorectal Cancer (mCRC) : Safety and Efficacy Result.
Eric Van Cutsem, et al. |
Chemoradiation with FOLFOX plus Cetuximab in Locally Advanced Cardia or Esophageal cancer. Final Results of a GERCOR phase II Trial (ERaFOX).
Aimery de Gramont, et al. |
AVANT: Results from a randomized, three-arm multinational phase III study to investigate bevacizumab with either XELOX or FOLFOX4 vs. FOLFOX4 alone as adjuvant treatment for colon cancer.
Aimery de Gramont, et al. |
Adjuvant FOLFIRI + Cetuximab in Patients with Resected Stage III Colon Cancer - NCCTG Intergroup phase III trial N0147.
Jocelin Huang, et al. |

A Single Arm Trial of Panitumumab in Cetuximab Refractory KRAS Wild-Type Colorectal Cancer.
Raymond Wadlow, et al. |
![]() Clinipathological features in metastatic colorectal cancer patients with KRAS wild type versus codon 12 and codon 13 mutant: Results from a multicenter, cross-sectional study by the Japan Study Group of KRAS Mutation in Colorectal Cancer.
Takayuki Yoshino, et al.
![]() Clinical outcome in patients with metastatic colorectal cancer harboring p.G13D KRAS mutation treated with Cetuximab.
Hideaki Bando, et al.
|
Impact of early tumor shrinkage on long-term outcome in metastatic colorectal cancer (mCRC) treated with FOLFOX4 with or without cetuximab: lessons from the OPUS trial.
Hubert Piessevaux, et al. |
Pooled Safety Results from SPIRITT: A Multicenter, Open-label, Randomized, Phase 2 Study of FOLFIRI with Panitumumab or Bevacizumab as 2nd-line Treatment in Patients with Metastatic Colorectal Cancer (mCRC)
J. Randolph Hecht, et al. |
